000285668 001__ 285668
000285668 005__ 20240229155115.0
000285668 0247_ $$2doi$$a10.1002/jmv.29230
000285668 0247_ $$2pmid$$apmid:38009614
000285668 0247_ $$2ISSN$$a0146-6615
000285668 0247_ $$2ISSN$$a1096-9071
000285668 0247_ $$2altmetric$$aaltmetric:156878980
000285668 037__ $$aDKFZ-2023-02491
000285668 041__ $$aEnglish
000285668 082__ $$a610
000285668 1001_ $$0P:(DE-He78)0dd31e782183886a3a3728cd5a97194d$$aStrobel, Tobias$$b0$$eFirst author$$udkfz
000285668 245__ $$aRevisiting the role of endogenous STAT3 in HPV-positive cervical cancer cells.
000285668 260__ $$aBognor Regis [u.a.]$$bWiley$$c2023
000285668 3367_ $$2DRIVER$$aarticle
000285668 3367_ $$2DataCite$$aOutput Types/Journal article
000285668 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701355383_1987
000285668 3367_ $$2BibTeX$$aARTICLE
000285668 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285668 3367_ $$00$$2EndNote$$aJournal Article
000285668 500__ $$a#EA:F065#LA:F065# / 2023 Nov;95(11):e29230
000285668 520__ $$aNovel treatment options for human papillomavirus (HPV)-induced cancers are urgently required. The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is considered to be constitutively active in HPV-positive cervical cancer cells and essential for their proliferation. Moreover, STAT3 was reported to undergo mutually stimulatory interactions with the HPV E6/E7 oncogenes. Thus, inhibiting STAT3 in HPV-positive cancer cells is under discussion to provide a powerful novel therapeutic strategy. We here show that the antifungal drug ciclopirox destabilizes the STAT3 protein by acting as an iron chelator. However, by exploring the functional consequences of STAT3 inhibition in HPV-positive cancer cells, we obtained several unexpected results. Chemical STAT3 inhibitors heterogeneously affect cervical cancer cell proliferation and those which act antiproliferative also block the growth of STAT3 knockout cells, indicating induction of off-target effects. In contrast to several chemical inhibitors, genetic inhibition of STAT3 expression by either RNA interference or the CRISPR/Cas9 method does not appreciably affect cervical cancer cell proliferation. Transcriptome analyses indicate that blocking STAT3 expression in HPV-positive cancer cells has very limited effects on putative STAT3 target genes. Although the targeted inhibition of specific growth-promoting signaling pathways leads to a feedback activation of STAT3 in cervical cancer cells via Janus kinase 1/2, this does not lead to treatment resistance. Moreover, we did not obtain experimental evidence for a STAT3-linked activation of HPV E6/E7 oncogene expression or, vice versa, an E6/E7-dependent activation of STAT3, at endogenous conditions in cervical cancer cells. Collectively, these findings question the essential role of STAT3 in cervical cancer cell proliferation and the strategy to inhibit STAT3 in these cells for therapeutic purposes.
000285668 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000285668 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285668 650_7 $$2Other$$aMEK
000285668 650_7 $$2Other$$aPI3K
000285668 650_7 $$2Other$$aSTAT3
000285668 650_7 $$2Other$$acervical cancer
000285668 650_7 $$2Other$$aciclopirox
000285668 650_7 $$2Other$$ahuman papillomavirus
000285668 7001_ $$0P:(DE-He78)42316484a6436f23360448fe7a21e337$$aWeber, Maria$$b1
000285668 7001_ $$0P:(DE-He78)ed83dd999c4609203587f090bc0ba04e$$aHeber, Nora$$b2$$udkfz
000285668 7001_ $$0P:(DE-He78)36388794be2cf5f298978498ff3c64a2$$aHolzer, Angela$$b3$$udkfz
000285668 7001_ $$0P:(DE-He78)97468f1980416a4376b44e701d25f24b$$aHoppe-Seyler, Karin$$b4$$udkfz
000285668 7001_ $$0P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac$$aHoppe-Seyler, Felix$$b5$$eLast author$$udkfz
000285668 773__ $$0PERI:(DE-600)1475090-9$$a10.1002/jmv.29230$$gVol. 95, no. 11, p. e29230$$n11$$pe29230$$tJournal of medical virology$$v95$$x0146-6615$$y2023
000285668 909CO $$ooai:inrepo02.dkfz.de:285668$$pVDB
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0dd31e782183886a3a3728cd5a97194d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)42316484a6436f23360448fe7a21e337$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed83dd999c4609203587f090bc0ba04e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)36388794be2cf5f298978498ff3c64a2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97468f1980416a4376b44e701d25f24b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000285668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000285668 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000285668 9141_ $$y2023
000285668 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000285668 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000285668 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MED VIROL : 2022$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000285668 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ MED VIROL : 2022$$d2023-10-21
000285668 9202_ $$0I:(DE-He78)F065-20160331$$kF065$$lF065 Molek. Therapie virusassozierter Tumore$$x0
000285668 9201_ $$0I:(DE-He78)F065-20160331$$kF065$$lF065 Molek. Therapie virusassozierter Tumore$$x0
000285668 9200_ $$0I:(DE-He78)F065-20160331$$kF065$$lF065 Molek. Therapie virusassozierter Tumore$$x0
000285668 980__ $$ajournal
000285668 980__ $$aVDB
000285668 980__ $$aI:(DE-He78)F065-20160331
000285668 980__ $$aUNRESTRICTED